Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Press Releases
Biosimilars Council Press Releases
Press Releases
Press Releases
May 24, 2021
AAM
AAM Names Erik Komendant Senior Vice President, Government Affairs
Press Releases
May 17, 2021
AAM
Monét Stanford Joins AAM as Director, Policy
Press Releases
April 29, 2021
AAM
AAM Statement on The Protecting Access to Affordable Medicines Act
Press Releases
April 27, 2021
AAM
AAM Statement on the Ensuring Access to Lower-Cost Medicines for Seniors Act
Press Releases
April 26, 2021
AAM
SB 764 Will Hurt Oregon’s Most Vulnerable Patients
Press Releases
March 26, 2021
AAM
AAM Statement on IQVIA Report Examining Biosimilar Reimbursement and Adoption
Press Releases
March 12, 2021
AAM
AAM Statement on Avalere Medicare Part D Analysis
Press Releases
February 26, 2021
AAM
AAM Statement on President Biden’s Supply Chain Executive Order
Press Releases
February 25, 2021
AAM
AAM Announces 2021 Board of Directors
Press Releases
February 24, 2021
AAM
AAM Announces 2021 Associate Members
Press Releases
February 24, 2021
AAM
AAM Statement on President-elect Biden Naming Katherine Tai as U.S. Trade Representative
Press Releases
February 22, 2021
AAM
AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH